Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Early-onset Lafora body disease.
Turnbull J, Girard JM, Lohi H, Chan EM, Wang P, Tiberia E, Omer S, Ahmed M, Bennett C, Chakrabarty A, Tyagi A, Liu Y, Pencea N, Zhao X, Scherer SW, Ackerley CA, Minassian BA.
Brain. 2012 Sep;135(Pt 9):2684-98. doi: 10.1093/brain/aws205.
Related citations
Deciphering the role of malin in the lafora progressive myoclonus epilepsy.
Romá-Mateo C, Sanz P, Gentry MS.
IUBMB Life. 2012 Oct;64(10):801-8. doi: 10.1002/iub.1072. Epub 2012 Jul 20. Review.
Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.
Tiberia E, Turnbull J, Wang T, Ruggieri A, Zhao XC, Pencea N, Israelian J, Wang Y, Ackerley CA, Wang P, Liu Y, Minassian BA.
J Biol Chem. 2012 Jul 20;287(30):25650-9. doi: 10.1074/jbc.M111.331611. Epub 2012 Jun 5.
Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
Zeng L, Wang Y, Baba O, Zheng P, Liu Y, Liu Y.
FEBS J. 2012 Jul;279(14):2467-78. doi: 10.1111/j.1742-4658.2012.08627.x. Epub 2012 Jun 8.
Lafora progressive myoclonus epilepsy: recent insights into cell degeneration.
Spuch C, Ortolano S, Navarro C.
Recent Pat Endocr Metab Immune Drug Discov. 2012 May;6(2):99-107. Review.
Laforin, a protein with many faces: glucan phosphatase, adapter protein, et alii.
Gentry MS, Romá-Mateo C, Sanz P.
FEBS J. 2013 Jan;280(2):525-37. doi: 10.1111/j.1742-4658.2012.08549.x. Epub 2012 Mar 16. Review.
The laforin-malin complex negatively regulates glycogen synthesis by modulating cellular glucose uptake via glucose transporters.
Singh PK, Singh S, Ganesh S.
Mol Cell Biol. 2012 Feb;32(3):652-63. doi: 10.1128/MCB.06353-11. Epub 2011 Nov 28.
Four novel and two recurrent NHLRC1 (EPM2B) and EPM2A gene mutations leading to Lafora disease in six Turkish families.
Salar S, Yeni N, Gündüz A, Güler A, Gökçay A, Velioğlu S, Gündoğdu A, Hande Çağlayan S.
Epilepsy Res. 2012 Feb;98(2-3):273-6. doi: 10.1016/j.eplepsyres.2011.09.020. Epub 2011 Nov 1.
Identification and characterization of novel splice variants of the human EPM2A gene mutated in Lafora progressive myoclonus epilepsy.
Dubey D, Parihar R, Ganesh S.
Genomics. 2012 Jan;99(1):36-43. doi: 10.1016/j.ygeno.2011.10.001. Epub 2011 Oct 19.
Dysfunctions in endosomal-lysosomal and autophagy pathways underlie neuropathology in a mouse model for Lafora disease.
Puri R, Suzuki T, Yamakawa K, Ganesh S.
Hum Mol Genet. 2012 Jan 1;21(1):175-84. doi: 10.1093/hmg/ddr452. Epub 2011 Sep 30.
Are there errors in glycogen biosynthesis and is laforin a repair enzyme?
Roach PJ.
FEBS Lett. 2011 Oct 20;585(20):3216-8. doi: 10.1016/j.febslet.2011.09.009. Epub 2011 Sep 16. Review.
Laforin, a dual specificity phosphatase involved in Lafora disease, is present mainly as monomeric form with full phosphatase activity.
Dukhande VV, Rogers DM, Romá-Mateo C, Donderis J, Marina A, Taylor AO, Sanz P, Gentry MS.
PLoS One. 2011;6(8):e24040. doi: 10.1371/journal.pone.0024040. Epub 2011 Aug 26.
Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease.
Valles-Ortega J, Duran J, Garcia-Rocha M, Bosch C, Saez I, Pujadas L, Serafin A, Cañas X, Soriano E, Delgado-García JM, Gruart A, Guinovart JJ.
EMBO Mol Med. 2011 Nov;3(11):667-81. doi: 10.1002/emmm.201100174. Epub 2011 Aug 29.
Lafora disease E3-ubiquitin ligase malin is related to TRIM32 at both the phylogenetic and functional level.
Romá-Mateo C, Moreno D, Vernia S, Rubio T, Bridges TM, Gentry MS, Sanz P.
BMC Evol Biol. 2011 Jul 28;11:225. doi: 10.1186/1471-2148-11-225.
Lafora disease ubiquitin ligase malin promotes proteasomal degradation of neuronatin and regulates glycogen synthesis.
Sharma J, Rao SN, Shankar SK, Satishchandra P, Jana NR.
Neurobiol Dis. 2011 Oct;44(1):133-41. doi: 10.1016/j.nbd.2011.06.013. Epub 2011 Jun 25.
A PTG variant contributes to a milder phenotype in Lafora disease.
Guerrero R, Vernia S, Sanz R, Abreu-Rodríguez I, Almaraz C, García-Hoyos M, Michelucci R, Tassinari CA, Riguzzi P, Nobile C, Sanz P, Serratosa JM, Gómez-Garre P.
PLoS One. 2011;6(6):e21294. doi: 10.1371/journal.pone.0021294. Epub 2011 Jun 30.
Laforin, a dual-specificity phosphatase involved in Lafora disease, is phosphorylated at Ser25 by AMP-activated protein kinase.
Romá-Mateo C, Solaz-Fuster Mdel C, Gimeno-Alcañiz JV, Dukhande VV, Donderis J, Worby CA, Marina A, Criado O, Koller A, Rodriguez De Cordoba S, Gentry MS, Sanz P.
Biochem J. 2011 Oct 15;439(2):265-75. doi: 10.1042/BJ20110150.
Malin and laforin are essential components of a protein complex that protects cells from thermal stress.
Sengupta S, Badhwar I, Upadhyay M, Singh S, Ganesh S.
J Cell Sci. 2011 Jul 1;124(Pt 13):2277-86. doi: 10.1242/jcs.082800. Epub 2011 Jun 7.
Lafora disease: a case report, pathologic and genetic study.
Harirchian MH, Shandiz EE, Turnbull J, Minassian BA, Shahsiah R.
Indian J Pathol Microbiol. 2011 Apr-Jun;54(2):374-5. doi: 10.4103/0377-4929.81645.
Rapidly progressive phenotype of Lafora disease associated with a novel NHLRC1 mutation.
Brackmann FA, Kiefer A, Agaimy A, Gencik M, Trollmann R.
Pediatr Neurol. 2011 Jun;44(6):475-7. doi: 10.1016/j.pediatrneurol.2011.01.012.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on